tradingkey.logo

Anika Therapeutics Inc

ANIK

8.900USD

-0.040-0.45%
Close 09/19, 16:00ETQuotes delayed by 15 min
128.32MMarket Cap
LossP/E TTM

Anika Therapeutics Inc

8.900

-0.040-0.45%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
41 / 207
Overall Ranking
102 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 3 analysts
Strong Buy
Current Rating
18.333
Target Price
+105.07%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Anika Therapeutics, Inc. is a global joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, and sports medicine. It is focused on developing, manufacturing and commercializing products on its hyaluronic acid (HA), technology platform. Its OA Pain Management product family consists of Monovisc and Orthovisc, its injectable, HA, OA Pain Management offerings are indicated to provide pain relief from osteoarthritis conditions; and Cingal, its novel, next generation, single-injection OA Pain Management product consisting of its proprietary cross-linked HA material combined with a steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products utilizing HA, including Integrity, its new hyaluronic acid-based scaffold for rotator cuff and other tendon repairs.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 279.47.
Overvalued
The company’s latest PE is -2.15, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 13.74M shares, decreasing 9.84% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 779.47K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.27, which is higher than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 28.22M, representing a year-over-year decrease of 32.69%, while its net profit experienced a year-over-year decrease of 4411.36%.

Score

Industry at a Glance

Previous score
8.27
Change
0

Financials

8.72

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

6.72

Operational Efficiency

10.00

Growth Potential

8.49

Shareholder Returns

7.41

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -2.16, which is 93.48% below the recent high of -4.18 and -523.12% above the recent low of -13.47.

Score

Industry at a Glance

Previous score
2.80
Change
1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 41/207
No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 9.33, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Anika Therapeutics Inc is 16.00, with a high of 24.00 and a low of 15.00.

Score

Industry at a Glance

Previous score
9.33
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts
Strong Buy
Current Rating
18.333
Target Price
+105.07%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

118
Total
7
Median
8
Average
Company name
Ratings
Analysts
Anika Therapeutics Inc
ANIK
3
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
24

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.64, which is lower than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 9.77 and the support level at 8.16, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.64
Change
-0.21

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(4)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
0.078
Neutral
RSI(14)
48.393
Neutral
STOCH(KDJ)(9,3,3)
64.476
Buy
ATR(14)
0.319
Low Volatility
CCI(14)
30.292
Neutral
Williams %R
53.097
Neutral
TRIX(12,20)
-0.219
Sell
StochRSI(14)
87.324
Overbought
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
8.760
Buy
MA10
8.717
Buy
MA20
8.963
Sell
MA50
9.387
Sell
MA100
10.616
Sell
MA200
13.414
Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 95.32%, representing a quarter-over-quarter increase of 1.16%. The largest institutional shareholder is The Vanguard, holding a total of 779.47K shares, representing 5.41% of shares outstanding, with 3.46% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Trigran Investments, Inc.
2.04M
+0.99%
Caligan Partners, LP
1.44M
--
BlackRock Institutional Trust Company, N.A.
957.43K
-4.90%
The Vanguard Group, Inc.
Star Investors
777.40K
+1.59%
Dimensional Fund Advisors, L.P.
613.97K
-6.60%
Opaleye Management Inc.
395.00K
--
Acadian Asset Management LLC
539.61K
+13.43%
BlackRock Financial Management, Inc.
522.01K
+2.30%
Boothbay Fund Management, LLC
529.50K
--
Renaissance Technologies LLC
Star Investors
528.62K
+0.02%
1
2

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.10, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.61. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.10
Change
0
Beta vs S&P 500 index
0.62
VaR
+3.83%
240-Day Maximum Drawdown
+68.27%
240-Day Volatility
+56.00%
Return
Best Daily Return
60 days
+8.12%
120 days
+8.13%
5 years
+11.22%
Worst Daily Return
60 days
-27.42%
120 days
-27.42%
5 years
-30.67%
Sharpe Ratio
60 days
-0.68
120 days
-1.22
5 years
-0.46
Risk Assessment
Maximum Drawdown
240 days
+68.27%
3 years
+74.77%
5 years
+83.15%
Return-to-Drawdown Ratio
240 days
-0.94
3 years
-0.31
5 years
-0.18
Skewness
240 days
-3.95
3 years
-3.44
5 years
-2.48
Volatility
Realised Volatility
240 days
+56.00%
5 years
+47.72%
Standardised True Range
240 days
+7.15%
5 years
+11.34%
Downside Risk-Adjusted Return
120 days
-119.47%
240 days
-119.47%
Maximum Daily Upside Volatility
60 days
+36.70%
Maximum Daily Downside Volatility
60 days
+61.52%
Liquidity
Average Turnover Rate
60 days
+0.84%
120 days
+0.69%
5 years
--
Turnover Deviation
20 days
+49.49%
60 days
+50.55%
120 days
+22.33%

Peer Comparison

Healthcare Equipment & Supplies
Anika Therapeutics Inc
Anika Therapeutics Inc
ANIK
7.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
8.24 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
8.01 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI